Encenicline (FRM 6124) fails in two Phase III trials to treat cognitive impairment with schizophrenia- Forum Pharma
Topline results were announced by Forum Pharma of two Phase III trials in patients with cognitive impairment with schizophrenia and they demonstrated for encenicline (FRM 6124) a favourable safety and tolerability profile but neither study met its co primary endpoint based on cognitive function and patient function. An unexpected placebo response was observed in both trials.The Company will implement significant restructuring.
Comment: The FDA still has the Alzheimer's program for encenicline on hold after a number of patients taking the drug reported severe gastrointestinal events last year.
Related news and insights
Amicus Therapeutics announced that the European Medicines Agency validated the Marketing Authorization Applications (MAA) for AT GAA (cipaglucosidase alfa + miglustat), the Company’s investigational two-component therapy for the treatment of Pompe disease.
Bristol Myers Squibb announced that the FDA has accepted for priority review the supplemental Biologics License Application (sBLA) for Reblozyl (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia.
BeiGene, Ltd. and EUSA Pharma (UK), Ltd. announced that the China National Medical Products Administration (NMPA) has approved Sylvant (siltuximab for injection) for the treatment of adult patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative, also known as idiopathic MCD (iMCD).